Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of AHCC on CD4+ and CD8+ levels in epithelial ovarian cancer patients receiving platinum-based chemotherapy
TCTR20141119001Phase 3Enrolling by invitation
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Apr 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of active hexose correlated compound in epithelial ovarian cancer (EOC), sponsored by Ratchadaphiseksomphot Endowment Fund. Started Apr 2014; status: enrolling by invitation.
02
Drugs
active hexose correlated compound
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on TCTR20141119001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20141119001.